Skip to Content

Join the 'Psoriatic Arthritis' group to help and get support from people like you.

Psoriatic Arthritis News

FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira

Posted 30 Aug 2017 by Drugs.com

Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including: moderate to severe active rheumatoid arthritis moderate to severe polyarticular juvenile idiopathic arthritis** active psoriatic arthritis active ankylosing spondylitis (an arthritis that affects the spine) moderate to severe active adult Crohn’s disease moderate to severe active ulcerative colitis moderate to severe plaque psoriasis “Cyltezo is the first biosimilar from Boehringer Ingelheim to be approved by the FDA and marks an important step towards our goal of providing new and more affordable treatment options to healthcare providers and patients,” said Ivan Blanarik, Senior Vice President and Head of The ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Psoriasis, Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Juvenile Rheumatoid Arthritis, Ulcerative Colitis - Maintenance, Juvenile Idiopathic Arthritis, Humira Pen, Adalimumab, Amjevita, Cyltezo

Bristol-Myers Squibb’s Orencia (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults

Posted 8 Jul 2017 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) July 6, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) announced today the U.S. Food and Drug Administration (FDA) has approved Orencia for the treatment of adults with active Psoriatic Arthritis (PsA)1, a chronic2, inflammatory disease that can affect both the skin and musculoskeletal system.3 Orencia is approved and available in both intravenous and subcutaneous (SC) injection formulations.1 Orencia should not be administered concomitantly with TNF antagonists, and is not recommended for use concomitantly with other biologic Rheumatoid Arthritis (RA) therapy, such as anakinra.1 This approval marks the third autoimmune disease indication for Orencia.1 “This approval underscores the efficacy of Orencia in adult patients with active Psoriatic Arthritis, who have been in need of new treatments,” said Brian J. Gavin, Vice President, Orencia Development Lea ... Read more

Related support groups: Psoriatic Arthritis, Orencia, Abatacept

Promising Results for Ixekizumab Against Psoriatic Arthritis

Posted 26 May 2017 by Drugs.com

FRIDAY, May 26, 2017 – A new drug might help ease the pain and disability of a form of arthritis often linked to psoriasis. According to Stanford University researchers, psoriatic arthritis is an inflammatory joint disorder tied to an out-of-control immune response. The disease affects about one in every 200 people and is often accompanied by the autoimmune skin disorder psoriasis. Psoriatic arthritis typically arises after the age of 30 and can bring stiffness, pain and swelling of the joints, leading to real disability if treatments don't help. The new study focused on more than 300 adult patients across 10 countries. These patients were no longer seeing an effect from standard biologic drugs or had never experienced a benefit in the first place. That's not uncommon. "Only about half of psoriatic arthritis patients who are given TNF inhibitors get better," study lead author Dr. Mark ... Read more

Related support groups: Psoriasis, Psoriatic Arthritis, Plaque Psoriasis, Taltz, Ixekizumab, Psoriatic Arthropathy

FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade

Posted 27 Apr 2017 by Drugs.com

INCHEON, Korea – April 24, 2017 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar referencing Remicade®i (infliximab), across all eligible indications. In the US, Renflexis is indicated for reducing signs and symptoms in patients with adult and pediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and for the treatment of adult plaque psoriasis. Renflexis is the first Samsung Bioepis product approved for marketing in the United States (US). “Since our company was established five years ago, we have strived day in and day out to realize the promise of biosimilars for patients across the United States by offering them treatment options at a lower cost. We hope this regulatory milestone will bring us a step closer to achievin ... Read more

Related support groups: Rheumatoid Arthritis, Crohn's Disease, Remicade, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Infliximab, Renflexis

Amjevita OK'd to Treat Inflammatory Diseases

Posted 27 Sep 2016 by Drugs.com

MONDAY, Sept. 26, 2016 – Amjevita (adalimumab-atto) – a biosimilar drug similar to the popular anti-inflammatory drug Humira – has been approved by the U.S. Food and Drug Administration. Amjevita has been approved for moderate-to-severe rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis (an arthritis that affects the spine); Crohn's disease; ulcerative colitis; plaque psoriasis and juvenile idiopathic arthritis, the FDA said in a news release. Biological drugs are generally derived from a living organism and can come from many sources, including humans, animals, microorganisms or yeast, the FDA said. A biosimilar drug is a biological product that's sanctioned after its maker proves it is "highly similar" to an already-approved biologic drug. The manufacturer of the biosimilar drug must prove that the product has "no clinically meaningful differences" in safety, purity ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Juvenile Idiopathic Arthritis, Adalimumab, Amjevita

FDA Approves Amjevita (adalimumab-atto), a Biosimilar to Humira

Posted 26 Sep 2016 by Drugs.com

September 23, 2016 – The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved for the following indications in adult patients: moderately to severely active rheumatoid arthritis; active psoriatic arthritis; active ankylosing spondylitis (an arthritis that affects the spine); moderately to severely active Crohn’s disease; moderately to severely active ulcerative colitis; and moderate to severe plaque psoriasis. Amjevita is also indicated for moderately to severely active polyarticular juvenile idiopathic arthritis in patients four years of age and older. Health care professionals should review the prescribing information in the labeling for detailed information about the approved uses. “This is the fourth FDA-approved biosimilar. The biosimilar pathway is still a new fr ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Psoriasis, Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Maintenance, Adalimumab, Amjevita

FDA Approves Erelzi (etanercept-szzs), a Biosimilar to Enbrel

Posted 1 Sep 2016 by Drugs.com

August 30, 2016 – The U.S. Food and Drug Administration today approved Erelzi, (etanercept-szzs) for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998. Erelzi is administered by injection for the treatment of: moderate to severe rheumatoid arthritis, either as a standalone therapy or in combination with methotrexate (MTX); moderate to severe polyarticular juvenile idiopathic arthritis in patients ages two and older; active psoriatic arthritis, including use in combination with MTX in psoriatic arthritis patients who do not respond adequately to MTX alone; active ankylosing spondylitis (an arthritis that affects the spine); and chronic moderate to severe plaque psoriasis in adult patients (18 years or older) who are candidates for systemic therapy or phototherapy. Health care professionals should review the prescribing ... Read more

Related support groups: Rheumatoid Arthritis, Enbrel, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Juvenile Idiopathic Arthritis, Etanercept, Erelzi

Inflectra Approved as 'Biosimilar' to Remicade

Posted 7 Apr 2016 by Drugs.com

WEDNESDAY, April 6, 2016 – The U.S. Food and Drug Administration has approved its second-ever "biosimilar" drug, Inflectra, for adults with Crohn's disease, rheumatoid arthritis or chronic plaque psoriasis, among other prescribed uses. In a media release, the agency said Inflectra was biosimilar to Janssen Biotech's Remicade (infliximab), first licensed in 1998. A biosimilar drug is sanctioned based on its maker's ability to show that it is "highly similar" to an already-approved biological drug that is generally derived from a living organism, such as a person, animal, microorganism or yeast, the FDA said. The maker of a biosimilar drug also must prove that the product has no "clinically meaningful difference" in safety and effectiveness from the original drug, and that the newer product has only "minor differences in clinically inactive components" from the original. Inflectra's most ... Read more

Related support groups: Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Remicade, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Infliximab, Inflectra

FDA Approves Inflectra (infliximab-dyyb) a Biosimilar to Remicade

Posted 7 Apr 2016 by Drugs.com

April 5, 2016 – The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. Inflectra is biosimilar to Janssen Biotech, Inc.’s Remicade (infliximab), which was originally licensed in 1998. Inflectra is approved and can be prescribed by a health care professional for the treatment of: adult patients and pediatric patients (ages six years and older) with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy; adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy; patients with moderately to severely active rheumatoid arthritis in combination with methotrexate; patients with active ankylosing spondylitis (arthritis of ... Read more

Related support groups: Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Remicade, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Infliximab, Inflectra

Novartis Receives FDA Approval for Cosentyx (secukinumab) to Treat Patients with Ankylosing Spondylitis and Psoriatic Arthritis

Posted 17 Jan 2016 by Drugs.com

EAST HANOVER, N.J., Jan. 15, 2016 Novartis announced today that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). AS and PsA are both life-long, painful and debilitating inflammatory diseases that affect the joints and/or spine. If not treated effectively, both conditions can lead to irreversible joint and/or spinal bone damage caused by years of inflammation.2,3,4 With these new approvals, Cosentyx is now the first and only interleukin-17A (IL-17A) antagonist approved for AS, as well as moderate to severe plaque psoriasis and PsA, which impacts as many as 30% of patients with psoriasis.5 Cosentyx was approved for adult patients with moderate to severe plaque psoriasis in January 2015 and more than 13,000 patients with this ... Read more

Related support groups: Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Cosentyx, Secukinumab

Psoriasis, Depression Often Go Hand in Hand: Study

Posted 1 Oct 2015 by Drugs.com

THURSDAY, Oct. 1, 2015 – Regardless of severity, patients with the often disfiguring skin condition psoriasis face an elevated risk for depression, new research suggests. The depression risk may be driven more by concerns about appearance than by the actual status of the skin, said study author Dr. Roger Ho, an assistant professor in the department of dermatology at New York University School of Medicine. "One small area of [psoriasis] involvement might mean a lot more to one person than an area three times the size for another person," said Ho. "I think the location of skin lesions, such as lesions in a more visible area or lesions in an area that impairs daily functioning, might play a bigger role." Between 2 percent and 4 percent of North Americans have psoriasis, Ho said. The autoimmune disorder causes red, raised patches of skin covered with silvery-white scales. These patches ... Read more

Related support groups: Depression, Major Depressive Disorder, Psoriasis, Psoriatic Arthritis, Postpartum Depression, Dysthymia, Plaque Psoriasis, Psoriatic Arthropathy

2 Experimental Drugs Offer Hope Against Psoriasis: Studies

Posted 30 Sep 2015 by Drugs.com

WEDNESDAY, Sept. 30, 2015 – Two experimental drugs show promise in treating psoriasis and a related condition, psoriatic arthritis, new studies report. The drugs, brodalumab and secukinumab (Cosentyx), represent a new approach to treatment, said Michael Siegel, director of research programs at the National Psoriasis Foundation. "These studies show how targeting parts of the immune system can have great effects, and that's really exciting for our patients," said Siegel, who wasn't involved in the research. Psoriasis, a chronic autoimmune condition, causes raised red patches of skin topped with silvery scales. These patches usually appear on the scalp, elbows, knees, face, lower back, hands and feet. Psoriatic arthritis is a form of the disease that includes joint pain, stiffness and swelling. The study findings appear in the Oct. 1 issue of the New England Journal of Medicine. In one ... Read more

Related support groups: Psoriasis, Psoriatic Arthritis, Plaque Psoriasis, Cosentyx, Secukinumab, Psoriatic Arthropathy

Health Tip: Is Arthritis Affecting Your Hands?

Posted 7 Jul 2015 by Drugs.com

-- Arthritis in the joints of the hands can be painful and make many daily tasks difficult. The American Academy of Orthopaedics says symptoms may include: Joint pain ranging from dull to burning. Pain tends to be worse after hand and finger use, and in the morning. Swelling of the joints. Sensations of grating, grinding or looseness of hand joints. Development of cysts on the hands and fingers. Read more

Related support groups: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Juvenile Rheumatoid Arthritis, Gouty Arthritis

Injuries Up Risk of Psoriatic Arthritis for People With Psoriasis

Posted 12 Jun 2015 by Drugs.com

FRIDAY, June 12, 2015 – Injuries increase the risk of psoriatic arthritis in people who have psoriasis, a new study suggests. Psoriatic arthritis – chronic arthritis associated with the skin condition psoriasis – can lead to severe, disabling joint damage. About 30 percent of people with psoriasis develop psoriatic arthritis, according to the researchers. The study included information collected between 1995 and 2013. The information was from more than 70,000 psoriasis patients, including more than 15,000 who suffered physical injury. During that time, more than 1,000 cases of psoriatic arthritis were diagnosed. The incidence rate of psoriatic arthritis was 30 per 10,000 person-years among those who had a physical injury. In people without injury, the rate of psoriatic arthritis was 22 per 10,000 person-years. The increased risk of psoriatic arthritis associated with injury was even ... Read more

Related support groups: Psoriasis, Psoriatic Arthritis

Drug Shows Promise Against Arthritis Common in People with Psoriasis

Posted 11 Jun 2014 by Drugs.com

WEDNESDAY, June 11, 2014 – A new drug called brodalumab appears to be effective in treating patients suffering from psoriatic arthritis, a study says. Patients who responded to brodalumab had a significant improvement in their skin and reduction in the swelling of the fingers and toes, a condition called dactylitis that is common in psoriatic arthritis, according to the study's lead researcher, Dr. Philip Mease, a rheumatologist at Swedish Medical Center in Seattle. "We have a medication with a different mechanism of action than currently available drugs, increasing our chances to control this disease, which can be disabling and significantly affects patients' function and quality of life," said Mease. "We know that many patients will lose response to some medications or develop adverse effects, so there is a need for medicines that work differently," he said. "We have a chance to ... Read more

Related support groups: Psoriatic Arthritis

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Spondyloarthritis

Related Drug Support Groups

prednisone, methotrexate, Humira, Enbrel, Remicade, cortisone, dexamethasone, triamcinolone, Otezla, view more... sulfasalazine, Orencia, Stelara, cyclosporine, Decadron, Cimzia, leflunomide, Simponi, azathioprine, hydroxyurea, Cosentyx, mycophenolate mofetil, infliximab, Acthar, adalimumab, acitretin, Acth, Acthar Gel, HP, Deltasone, Kenalog-40, etanercept, apremilast, secukinumab, ustekinumab, Inflectra, golimumab, Rayos, Dexpak Taperpak, Sterapred, certolizumab, Liquid Pred, Adrenocot LA, Sterapred DS, Amjevita, Renflexis, Methotrexate LPF Sodium, Dexone, Adrenocot, Erelzi, Trexall, abatacept, Baycadron, Dalalone, Dexamethasone Intensol, Dalalone DP, Dalalone LA, Decaject, Decaject LA, Zema Pak, Clinacort, Dexasone LA, Cortone Acetate, Solurex, auranofin, corticotropin, Ridaura, Folex PFS, Rheumatrex Dose Pack, Hexadrol, Decadron-LA, Solurex LA, Dexacen-4, De-Sone LA, Prednicot, Dexacort-LA, Dexasone, Dexone LA, Primethasone, Dexacorten, Medidex, Medidex LA, Meticorten, Orasone, Prednicen-M, Cyltezo